Kyushu Pass: Dexamethasone Sodium Phosphate Injection Obtains Drug Registration Certificate.

Kyushu Communications announced on June 20th that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received the "Drug Registration Certificate" for Dexamethasone Sodium Phosphate Injection issued by the National Medical Products Administration for its subsidiary Huixianhe Pharmaceutical Co., Ltd. This drug is a national medical insurance class A variety mainly used for the treatment of allergic and autoimmune inflammatory diseases.